Company Description

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States.

It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee.

The company was incorporated in 2004 and is based in Herzliya, Israel.

Regentis Biomaterials Ltd.

Country	Israel
Founded	2004
IPO Date	Dec 4, 2025
Industry	Medical Instruments & Supplies
Sector	Healthcare
Employees	7
CEO	Ehud Geller

Contact Details

Address: 60, Medinat Hayehudim, Entrance C Herzliya, 4676652 Israel
Phone	972 9 960 1917
Website	regentis.co.il

Stock Details

Ticker Symbol	RGNT
Exchange	NYSEAMERICAN
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$8.00
CIK Code	1912966
CUSIP Number	001219096
ISIN Number	IL0012190968
SIC Code	3842

Key Executives

Name	Position
Dr. Ehud Geller Ph.D.	Chief Executive Officer and Executive Chairman
Arie Gordashnikov CPA	Chief Accounting Officer
Dr. Dror Seliktar Ph.D.	Co-Founder and Chief Scientific Officer
Ori Gon	Chief Financial Officer and Chief Business Officer
Dr. Galit Reske Ph.D.	Chief Medical Officer

Latest SEC Filings

Date	Type	Title
Aug 13, 2026	SCHEDULE 13G	Filing
Aug 11, 2026	S-8	Securities to be offered to employees in employee benefit plans
Jul 20, 2026	6-K	Report of foreign issuer
Jul 15, 2026	6-K	Report of foreign issuer
Jul 13, 2026	EFFECT	Notice of Effectiveness
Jul 13, 2026	424B3	Prospectus
Jul 9, 2026	6-K	Report of foreign issuer
Jul 8, 2026	F-1	Registration statement for certain foreign private issuers
Jul 2, 2026	6-K	Report of foreign issuer
Jun 25, 2026	D	Notice of Exempt Offering of Securities

View All SEC Filings